Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy

Chung Ze Wu, Li Chien Chang, Yuh Feng Lin, Yi Jen Hung, Dee Pei, Nain Feng Chu, Jin Shuen Chen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives: Soluble urokinase plasminogen activator receptor (suPAR), derived from membrane bound uPAR, is associated with inflammatory diseases. In the present study, we explored the expression of uPAR/suPAR in common biopsy-proven kidney diseases and the relationship between suPAR and staging of type 2 diabetic nephropathy (DN). Design and methods: Serum samples for suPAR and renal tissues for uPAR staining were investigated in various common kidney diseases. The levels of serum suPAR were measured and adequate cut-off values of different stage of DN were calculated by receiver operating characteristic (ROC) curve. Results: In our results, the expression of uPAR on renal tissues was pronounced in the majority of kidney diseases. Comparing of expression of uPAR among different kidney diseases, it was strongest in minimal change disease (MCD) and weakest in chronic interstitial nephritis. Serum suPAR in most kidney diseases, except of MCD, was significantly elevated and was highest in DN. As for DN and suPAR, we found that suPAR progressively increased with staging of DN. Moreover, suPAR was linearly and negatively related to estimated glomerular filtration rate and positively related to the amount of proteinuria. By ROC curve, the cut-off values of suPAR in DN for assessing development increased with the progression of the disease. Conclusions: We concluded that uPAR/suPAR is elevated in most kidney diseases and that suPAR is a useful biomarker for assessing stages of DN.

Original languageEnglish
Pages (from-to)1324-1329
Number of pages6
JournalClinical Biochemistry
Volume48
Issue number18
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Urokinase Plasminogen Activator Receptors
Biopsy
Kidney Diseases
Diabetic Nephropathies
Lipoid Nephrosis
ROC Curve
Serum
Tissue
Kidney
Interstitial Nephritis
Biomarkers
Glomerular Filtration Rate
Proteinuria
Disease Progression

Keywords

  • Diabetic nephropathy
  • Proteinuria
  • Soluble urokinase plasminogen activator receptor

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy. / Wu, Chung Ze; Chang, Li Chien; Lin, Yuh Feng; Hung, Yi Jen; Pei, Dee; Chu, Nain Feng; Chen, Jin Shuen.

In: Clinical Biochemistry, Vol. 48, No. 18, 01.12.2015, p. 1324-1329.

Research output: Contribution to journalArticle

Wu, Chung Ze ; Chang, Li Chien ; Lin, Yuh Feng ; Hung, Yi Jen ; Pei, Dee ; Chu, Nain Feng ; Chen, Jin Shuen. / Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy. In: Clinical Biochemistry. 2015 ; Vol. 48, No. 18. pp. 1324-1329.
@article{9ba504af67a949b3bd20b9c4f17ac1e1,
title = "Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy",
abstract = "Objectives: Soluble urokinase plasminogen activator receptor (suPAR), derived from membrane bound uPAR, is associated with inflammatory diseases. In the present study, we explored the expression of uPAR/suPAR in common biopsy-proven kidney diseases and the relationship between suPAR and staging of type 2 diabetic nephropathy (DN). Design and methods: Serum samples for suPAR and renal tissues for uPAR staining were investigated in various common kidney diseases. The levels of serum suPAR were measured and adequate cut-off values of different stage of DN were calculated by receiver operating characteristic (ROC) curve. Results: In our results, the expression of uPAR on renal tissues was pronounced in the majority of kidney diseases. Comparing of expression of uPAR among different kidney diseases, it was strongest in minimal change disease (MCD) and weakest in chronic interstitial nephritis. Serum suPAR in most kidney diseases, except of MCD, was significantly elevated and was highest in DN. As for DN and suPAR, we found that suPAR progressively increased with staging of DN. Moreover, suPAR was linearly and negatively related to estimated glomerular filtration rate and positively related to the amount of proteinuria. By ROC curve, the cut-off values of suPAR in DN for assessing development increased with the progression of the disease. Conclusions: We concluded that uPAR/suPAR is elevated in most kidney diseases and that suPAR is a useful biomarker for assessing stages of DN.",
keywords = "Diabetic nephropathy, Proteinuria, Soluble urokinase plasminogen activator receptor",
author = "Wu, {Chung Ze} and Chang, {Li Chien} and Lin, {Yuh Feng} and Hung, {Yi Jen} and Dee Pei and Chu, {Nain Feng} and Chen, {Jin Shuen}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.clinbiochem.2015.07.001",
language = "English",
volume = "48",
pages = "1324--1329",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "18",

}

TY - JOUR

T1 - Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy

AU - Wu, Chung Ze

AU - Chang, Li Chien

AU - Lin, Yuh Feng

AU - Hung, Yi Jen

AU - Pei, Dee

AU - Chu, Nain Feng

AU - Chen, Jin Shuen

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objectives: Soluble urokinase plasminogen activator receptor (suPAR), derived from membrane bound uPAR, is associated with inflammatory diseases. In the present study, we explored the expression of uPAR/suPAR in common biopsy-proven kidney diseases and the relationship between suPAR and staging of type 2 diabetic nephropathy (DN). Design and methods: Serum samples for suPAR and renal tissues for uPAR staining were investigated in various common kidney diseases. The levels of serum suPAR were measured and adequate cut-off values of different stage of DN were calculated by receiver operating characteristic (ROC) curve. Results: In our results, the expression of uPAR on renal tissues was pronounced in the majority of kidney diseases. Comparing of expression of uPAR among different kidney diseases, it was strongest in minimal change disease (MCD) and weakest in chronic interstitial nephritis. Serum suPAR in most kidney diseases, except of MCD, was significantly elevated and was highest in DN. As for DN and suPAR, we found that suPAR progressively increased with staging of DN. Moreover, suPAR was linearly and negatively related to estimated glomerular filtration rate and positively related to the amount of proteinuria. By ROC curve, the cut-off values of suPAR in DN for assessing development increased with the progression of the disease. Conclusions: We concluded that uPAR/suPAR is elevated in most kidney diseases and that suPAR is a useful biomarker for assessing stages of DN.

AB - Objectives: Soluble urokinase plasminogen activator receptor (suPAR), derived from membrane bound uPAR, is associated with inflammatory diseases. In the present study, we explored the expression of uPAR/suPAR in common biopsy-proven kidney diseases and the relationship between suPAR and staging of type 2 diabetic nephropathy (DN). Design and methods: Serum samples for suPAR and renal tissues for uPAR staining were investigated in various common kidney diseases. The levels of serum suPAR were measured and adequate cut-off values of different stage of DN were calculated by receiver operating characteristic (ROC) curve. Results: In our results, the expression of uPAR on renal tissues was pronounced in the majority of kidney diseases. Comparing of expression of uPAR among different kidney diseases, it was strongest in minimal change disease (MCD) and weakest in chronic interstitial nephritis. Serum suPAR in most kidney diseases, except of MCD, was significantly elevated and was highest in DN. As for DN and suPAR, we found that suPAR progressively increased with staging of DN. Moreover, suPAR was linearly and negatively related to estimated glomerular filtration rate and positively related to the amount of proteinuria. By ROC curve, the cut-off values of suPAR in DN for assessing development increased with the progression of the disease. Conclusions: We concluded that uPAR/suPAR is elevated in most kidney diseases and that suPAR is a useful biomarker for assessing stages of DN.

KW - Diabetic nephropathy

KW - Proteinuria

KW - Soluble urokinase plasminogen activator receptor

UR - http://www.scopus.com/inward/record.url?scp=84949113689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949113689&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2015.07.001

DO - 10.1016/j.clinbiochem.2015.07.001

M3 - Article

C2 - 26162494

AN - SCOPUS:84949113689

VL - 48

SP - 1324

EP - 1329

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 18

ER -